Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PERKINELMER, INC.

(PKI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

PerkinElmer : Collaborates With Leading Life Science Incubators LabCentral and MBC BioLabs to Help Further Drug Discovery

10/14/2021 | 03:12pm EST

Will provide automated protein characterization, cell imaging and cell counting technologies, along with expertise and training

October 14, 2021

WHAT: PerkinElmer, Inc. a global leader committed to innovating for a healthier world, today announced it is collaborating with leading life science incubators LabCentral in Boston, Massachusetts and MBC BioLabs in San Francisco, California to provide innovative, drug discovery technologies, expertise and training to help pharma and biotech start-ups more quickly and accurately identify and accelerate potential clinical trial candidates.

HOW: The PerkinElmer technologies to be used at both dynamic springboard communities will help optimize scientific workflows. These will include the LabChip® GXII Touch™ system, which allows for protein characterization in as little as 42 seconds and requires minimal sample prep, and the MuviCyteTM Live Cell Imaging System, with three-color fluorescence imaging and multiple movie modes, optimal cell maintenance support and flexible assay performance.

LabCentral and MBC BioLabs will also use the Victor® NIVO™ plate reader, the industry's most compact plate reader supporting all popular detection modes, and the Envision® Multimode Plate Reader, along with reagents from PerkinElmer's extensive portfolio. In addition, at LabCentral, PerkinElmer's Nexcelom® Celigo® Image Cytometer, a multichannel brightfield and fluorescent imaging technology for 2D and 3D cultures, and Cellaca® MX High-throughput Cell Counter, which processes 24 samples with fluorescence in 2.5 minutes or less, will be employed.

These innovative additions join other PerkinElmer technologies already at work at one or both of the communities, including cell line engineering, siRNA, and shRNA solutions and reagents from Horizon Discovery and Cellometer® Auto 2000 Cell Viability Counter systems from Nexcelom.

WHY: Commenting on the expanding collaboration with the leading incubators, Alan Fletcher, Ph.D., senior vice president, life science at PerkinElmer, said, "Getting leading edge drug discovery technologies and best practices into the hands of up-and-coming organizations is an exciting way to further new thinking around how to treat and prevent the world's most challenging diseases and viruses. We are thrilled to be involved with both the MBC BioLabs and LabCentral communities as their scientists and business teams work to bubble-up novel technologies and breakthrough drug candidates to improve human health."

Douglas Crawford, Ph.D., co-founder and general manager, MBC BioLabs, added, "We are committed to helping startups quickly generate vital data and thrilled to collaborate with PerkinElmer to bring state-of-the-art equipment to the 100+ companies in our labs. These research tools enable our companies to move swiftly from concept to results."

Johannes Fruehauf, MD, PhD, co-founder, president, LabCentral, also said, "The innovations and expertise PerkinElmer is bringing to LabCentral will further enable our resident companies in the development of their ground-breaking life science technologies and drug discovery work. We are excited to welcome PerkinElmer to our network, expanding on the dynamic cell and gene technologies already in action here from Nexcelom and Horizon Discovery."

MORE: From research to clinical trials and the manufacturing of new drugs and vaccines, PerkinElmer is helping scientists accelerate the discovery-to-commercialization process. To learn more about PerkinElmer's life sciences efforts around the globe, please visit: https://www.perkinelmer.com/corporate/what-we-do/markets/life-sciences.html.

About PerkinElmer

PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 15,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at www.perkinelmer.com.

###

Media Contact
Jennifer McNeil
jennifer.mcneil@perkinelmer.com
1 508.380.2902

Disclaimer

PerkinElmer Inc. published this content on 14 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 October 2021 19:11:06 UTC.


ę Publicnow 2021
All news about PERKINELMER, INC.
01/11PERKINELMER : 2022 JPM Healthcare Conference Presentation
PU
01/11PerkinElmer Boosts Q4, Full-Year 2021 Revenue Outlook
MT
01/11PERKINELMER : Updates Fourth Quarter Outlook; To Hold Earnings Call on Tuesday, February 1..
PU
01/11PERKINELMER INC : Results of Operations and Financial Condition (form 8-K)
AQ
01/11PerkinElmer Updates Fourth Quarter Outlook; To Hold Earnings Call on Tuesday, February ..
BU
01/11PerkinElmer, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 20..
CI
01/03Evercore ISI Adjusts PerkinElmer PT to $195 From $194, Maintains Outperform Rating
MT
2021PerkinElmer to Present Virtually at J.P. Morgan Healthcare Conference
BU
2021PerkinElmer India Welcomes Everest Instruments as its Primary, In-Country Channel Partn..
CI
2021Goldman Sachs Reinstates PerkinElmer at Neutral With $200 Price Target
MT
More news
Analyst Recommendations on PERKINELMER, INC.
More recommendations
Financials (USD)
Sales 2021 4 976 M - -
Net income 2021 980 M - -
Net Debt 2021 4 150 M - -
P/E ratio 2021 21,1x
Yield 2021 0,16%
Capitalization 22 523 M 22 523 M -
EV / Sales 2021 5,36x
EV / Sales 2022 6,02x
Nbr of Employees 14 000
Free-Float -
Chart PERKINELMER, INC.
Duration : Period :
PerkinElmer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PERKINELMER, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 178,47 $
Average target price 187,17 $
Spread / Average Target 4,87%
EPS Revisions
Managers and Directors
Prahlad Ramadhar Singh President, CEO, COO & Director
James M. Mock Chief Financial Officer & Senior Vice President
Alexis Platon Michas Non-Executive Chairman
Joel S. Goldberg Secretary, SVP-Administration & General Counsel
Peter Barrett Independent Director
Sector and Competitors
1st jan.Capi. (M$)
PERKINELMER, INC.-11.24%22 523
THERMO FISHER SCIENTIFIC-10.86%234 380
DANAHER CORPORATION-10.85%209 593
INTUITIVE SURGICAL, INC.-14.35%109 936
SIEMENS HEALTHINEERS AG-9.48%76 335
EDWARDS LIFESCIENCES CORPORATION-8.71%73 834